|
US6077A
(en)
|
|
1849-01-30 |
|
Improved hinged claw-wrench |
|
US835A
(en)
|
|
1838-07-12 |
|
X i i i x |
|
US761218A
(en)
|
1899-10-05 |
1904-05-31 |
U S Standard Voting Machine Co |
Register or counter.
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US6284236B1
(en)
|
1995-06-29 |
2001-09-04 |
Immunex Corporation |
Cytokine that induces apoptosis
|
|
KR970029803A
(ko)
|
1995-11-03 |
1997-06-26 |
김광호 |
반도체 메모리장치의 프리차지 회로
|
|
CA2249206A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
|
US6342363B1
(en)
|
1997-01-28 |
2002-01-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 nucleic acids and methods
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
US6740739B1
(en)
|
1998-01-15 |
2004-05-25 |
Genentech, Inc. |
Substitutional variants of APO-2 ligand
|
|
WO1999062526A2
(en)
|
1998-06-05 |
1999-12-09 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to cd38 to treat multiple myeloma
|
|
CA2361421A1
(en)
|
1999-02-03 |
2000-08-10 |
Biosante Pharmaceuticals, Inc. |
Therapeutic calcium phosphate particles and methods of manufacture and use
|
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
|
ATE330972T1
(de)
|
1999-06-09 |
2006-07-15 |
Genentech Inc |
Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
|
|
US6444640B1
(en)
|
1999-09-30 |
2002-09-03 |
Ludwig Institute For Cancer Research |
Compositions of trail and DNA damaging drugs and uses thereof
|
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
|
US20020155109A1
(en)
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
|
AU2002256895B2
(en)
|
2001-05-18 |
2008-09-18 |
Kirin Beer Kabushiki Kaisha |
Anti-TRAIL-R antibodies
|
|
MXPA03010747A
(es)
*
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
|
US7361341B2
(en)
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
|
WO2003066661A2
(en)
|
2001-07-03 |
2003-08-14 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
CN100506277C
(zh)
|
2001-11-01 |
2009-07-01 |
Uab研究基金会 |
肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系
|
|
US20040019915A1
(en)
|
2002-04-01 |
2004-01-29 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
|
|
CN101928344B
(zh)
|
2002-10-17 |
2014-08-13 |
根马布股份公司 |
抗cd20的人单克隆抗体
|
|
US20050266008A1
(en)
|
2004-03-29 |
2005-12-01 |
Medarex, Inc. |
Human anti-IRTA-5 antibodies
|
|
KR20070010046A
(ko)
|
2004-04-06 |
2007-01-19 |
제넨테크, 인크. |
Ｄｒ5 항체 및 그의 용도
|
|
PL1776384T3
(pl)
*
|
2004-08-04 |
2013-10-31 |
Mentrik Biotech Llc |
WARIANTY REGIONÓW Fc
|
|
US7741568B2
(en)
|
2005-01-13 |
2010-06-22 |
The Wiremold Company |
Downward facing receptacle assembly for cable raceway
|
|
ES2665422T3
(es)
|
2005-03-03 |
2018-04-25 |
Immunomedics Inc. |
Anticuerpos L243 humanizados
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
|
KR101516823B1
(ko)
|
2006-03-17 |
2015-05-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
안정화된 폴리펩티드 조성물
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
KR100847010B1
(ko)
|
2006-07-05 |
2008-07-17 |
아주대학교산학협력단 |
세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
|
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
TW200904072A
(en)
|
2007-07-05 |
2009-01-16 |
Ic Plus Corp |
System and method for generating interrupt
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
EP2166021A1
(en)
*
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
|
EP2376109B1
(en)
|
2008-12-19 |
2019-01-23 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
WO2010138725A1
(en)
|
2009-05-28 |
2010-12-02 |
Amgen Inc. |
Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
DK2560993T3
(da)
|
2010-04-20 |
2024-10-14 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
PL2606064T3
(pl)
|
2010-08-16 |
2015-07-31 |
Novimmune Sa |
Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
MX340556B
(es)
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
|
WO2012040518A2
(en)
*
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
|
NZ610153A
(en)
*
|
2010-10-29 |
2014-07-25 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
CN102250246A
(zh)
|
2011-06-10 |
2011-11-23 |
常州亚当生物技术有限公司 |
抗VEGF/PDGFRβ双特异性抗体及其应用
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
CN102654260B
(zh)
|
2011-09-29 |
2014-09-03 |
北京京东方光电科技有限公司 |
一种背光源和液晶显示器
|
|
LT2794905T
(lt)
|
2011-12-20 |
2020-07-10 |
Medimmune, Llc |
Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
|
|
SI2838917T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
|
|
ES2758979T3
(es)
|
2012-07-06 |
2020-05-07 |
Genmab Bv |
Proteína dimérica con mutaciones triples
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
EP2684896A1
(en)
*
|
2012-07-09 |
2014-01-15 |
International-Drug-Development-Biotech |
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
EP3048116A1
(en)
*
|
2015-01-23 |
2016-07-27 |
International-Drug-Development-Biotech |
Anti-dr5 antibodies with enhanced apoptosis potency
|
|
MA43365A
(fr)
|
2015-12-01 |
2018-10-10 |
Genmab Bv |
Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
|
|
SG11201903693QA
(en)
|
2016-11-01 |
2019-05-30 |
Genmab Bv |
Polypeptide variants and uses thereof
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|